Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation (CRISTEL)

11 maja 2026 zaktualizowane przez: Hopital Foch
The objective of this research is to obtain standardized and independent data on the number of pregnancies occurring in France and their follow-up up to 1 year postpartum (or post-pregnancy termination). This study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will enable the dissemination of clear and up-to-date information to the medical community, thus contributing to better patient counseling and, more broadly, to couples. They will also serve to issue recommendations to optimize the planning and follow-up of pregnancies in women with solid organ transplants. Finally, this initiative aims to promote clinical research on pregnancies.

Przegląd badań

Status

Jeszcze nie rekrutacja

Interwencja / Leczenie

Szczegółowy opis

According to North American and Australian registries, pregnancy is both a joyful and high-risk event for women who have received a solid organ transplant. Typically, a transplanted woman has a probability comparable to that of the general population of giving birth to a live infant, but she is likely to deliver prematurely (median gestational age: 32 weeks), to have a growth-restricted baby (median birth weight around 2.3 kg), and often in a context of preeclampsia (in at least 30% of cases)(1).

Today, these are the data shared with patients planning a pregnancy, despite uncertainty as to their accuracy and applicability in France or even Europe.

Among the unknowns that remain despite these registry data, the following should be noted:

Uncertainty about the level of pregnancy planning in this specific context: What proportion of women of childbearing age have been informed of the possibility of becoming pregnant, of the associated risks, and of necessary precautions (e.g., stopping mycophenolate mofetil at least 6 weeks before conception);

Variability in the information provided from one center to another, due to the absence of a national, consensus-based document addressing fertility and contraception in the post-transplantation setting;

Monitoring frequency specific to the graft, especially regarding exposure to immunosuppressive drugs (and consequently actual exposure to calcineurin inhibitors, the cornerstone of anti-rejection therapy, whose residual blood concentration varies from the second trimester onward)(2);

The true risk of preeclampsia, at a time when diagnosis can be refined by measuring levels of placental-derived anti-angiogenic factors in maternal serum (sFlt-1/PlGF ratio)(3), and by uterine artery Doppler;

The incidence of de novo anti-HLA immunization (HLA antigens expressed by the fetus and inherited from the father), which can now be assessed using the Luminex technique(4);

Maternal morbidity: What is the impact of pregnancy on graft function? Conversely, how does renal function influence pregnancy outcomes, regardless of the transplanted organ?

Infant morbidity in the short and medium term.

To establish these data and to provide accurate information to patients, we aim to conduct a study among pregnant women who have undergone solid organ transplantation (kidney, heart, lung, liver, or pancreas). The objective of this research is to collect standardized and independent data on the number of pregnancies occurring in France and to monitor them up to one year postpartum (or after pregnancy termination).

The study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will help disseminate clear and up-to-date information to the medical community, thus improving patient counseling and, more broadly, support for couples. They will also serve to develop recommendations to optimize the planning and management of pregnancies in women with solid organ transplants.

Finally, this initiative aims to promote clinical research on pregnancy in the context of transplantation, particularly through clinical trials and the development of biobanks.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

2000

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Female patient aged 18 years or older and of childbearing age
  • Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney)
  • Has a positive blood beta-hCG test result > 5 IU/L ("positive")
  • Has signed an informed consent form
  • Affiliated with a health insurance plan

Exclusion Criteria:

  • Patient deprived of liberty or under legal guardianship
  • Patient refuses to participate in the study

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Ekranizacja
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Inny: Adult female patients who have received a solid organ transplant
Adult female patients who have received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney), and who present with a positive beta-hCG blood test result (defined by a threshold of 5 IU/L) in one of the participating centers, or who are planning a pregnancy, will initially be identified.

Two optional (non-mandatory) biological samples may be collected as part of this study:

A 2 mL venous blood sample may be taken during a routine prenatal follow-up visit (around 30 weeks of gestation) in order to analyze the preeclampsia biomarker (sFlt-1/PlGF ratio), whenever preeclampsia is suspected.

A 5 mL sample from cord blood may be collected after delivery to analyze, in the newborn, the complete blood count, white blood cell differential, lymphocyte phenotyping (T CD3+, CD19+CD20+, and NK CD46+), and immunoglobulin levels (G, A, and M for humoral immunity, and E for allergy-related function).

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
Ramy czasowe: Annually over the 10-year study period
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
Annually over the 10-year study period

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Rate of preeclampsia
Ramy czasowe: Through study completion, an average of 1 year
Rate of preeclampsia
Through study completion, an average of 1 year
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
Ramy czasowe: 3 months and 12 months postopartum
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
3 months and 12 months postopartum
Live birth rate among transplanted mothers from the onset of pregnancy.
Ramy czasowe: through study completion, an average of 1 year
Live birth rate among transplanted mothers from the onset of pregnancy.
through study completion, an average of 1 year
Trajectory of serum creatinine levels
Ramy czasowe: During pregnancy (up to 40 weeks if gestation)
Trajectory of serum creatinine levels
During pregnancy (up to 40 weeks if gestation)
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
Ramy czasowe: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
Ramy czasowe: Day of delivery: Perioperative/Periprocedural
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
Day of delivery: Perioperative/Periprocedural
Birth weight of the newborn (in grams)
Ramy czasowe: day of delivery
Birth weight of the newborn (in grams)
day of delivery
Rate of spontaneous miscarriage
Ramy czasowe: Through study completion, an average of 1 year
Rate of spontaneous miscarriage
Through study completion, an average of 1 year
Rate of cesarean section
Ramy czasowe: Through study completion, an average of 1 year
Rate of cesarean section
Through study completion, an average of 1 year
Rate of prematurity
Ramy czasowe: Through study completion, an average of 1 year
Rate of prematurity
Through study completion, an average of 1 year
Rate of intrauterine growth restriction
Ramy czasowe: Through study completion, an average of 1 year
Rate of intrauterine growth restriction
Through study completion, an average of 1 year
the duration of hospital stay for both the mother and the newborn
Ramy czasowe: Through study completion, an average of 1 year
the duration of hospital stay for both the mother and the newborn
Through study completion, an average of 1 year
incidence of biopsy-proven acute rejection up to 12 months postpartum;
Ramy czasowe: up to 12 months postpartum;
incidence of biopsy-proven acute rejection up to 12 months postpartum;
up to 12 months postpartum;
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
Ramy czasowe: 3 months and 12 months postoartum
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
3 months and 12 months postoartum
Trajectory of proteinuria (protein-to-creatinine ratio)
Ramy czasowe: During pregnancy (up to 40 weeks if gestation)
Trajectory of proteinuria (protein-to-creatinine ratio)
During pregnancy (up to 40 weeks if gestation)
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
Ramy czasowe: During pregnancy (up to 40 weeks if gestation)
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
During pregnancy (up to 40 weeks if gestation)
Trajectory of anti-angiogenic factors during pregnancy
Ramy czasowe: During pregnancy (up to 40 weeks if gestation)
Trajectory of anti-angiogenic factors during pregnancy
During pregnancy (up to 40 weeks if gestation)
Rate of maternal complications and hospitalizations before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
Ramy czasowe: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Rate of maternal hospitalizations before delivery and in the postpartum period
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Apgar score
Ramy czasowe: day of delivery
Apgar score
day of delivery
Proportion of growth-restricted
Ramy czasowe: day of delivery and up 3 month postpartum
Proportion of growth-restricted
day of delivery and up 3 month postpartum
Incidence of neonatal complications before the third month of life
Ramy czasowe: day of delivery and up 3 month postpartum
Incidence of neonatal complications before the third month of life
day of delivery and up 3 month postpartum

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Alexandre Pr Hertig, MED, Foch Hospital

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 września 2026

Zakończenie podstawowe (Szacowany)

1 września 2036

Ukończenie studiów (Szacowany)

1 września 2036

Daty rejestracji na studia

Pierwszy przesłany

22 września 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 maja 2026

Pierwszy wysłany (Rzeczywisty)

18 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 maja 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj